Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.


Options:
A: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: Cohort A (0.4/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort B (0.4/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort C (0.4/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort D (0.8/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort E (0.8/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort F (0.8/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort G (1.2/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort H (1.2/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort I (1.2/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort A (0.4/150, 1x/ Week), Cohort B (0.4/150, 1x/ 3 Weeks), Cohort C (0.4/150, 1x/ 4 Weeks), Cohort D (0.8/150, 1x/ Week), Cohort E (0.8/150, 1x/ 3 Weeks), Cohort F (0.8/150, 1x/ 4 Weeks), Cohort G (1.2/150, 1x/ Week), Cohort H (1.2/150, 1x/ 3 Weeks), Cohort I (1.2/150, 1x/ 4 Weeks)
C: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa
D: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin

Answer: D